OUR BLOG

HEAR AWESOME STORIES HERE
Home / Blog
image title

PsychedeLinks – March 17, 2023

PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge Law Group’s groundbreaking Psychedelics Group.

 Emerge’s Hot Take

Oregon Closer to Magic Mushroom Therapy, But Has Setback
Last week, more than 100 future Oregon facilitators graduated from InnerTrek’s psilocybin facilitator training program. Congrats to those students! Soon enough those facilitators will be licensed by the Oregon Health Authority (OHA) and ready to provide psilocybin services to clients. But without any currently licensed OHA services centers or manufacturers, there are no clients for facilitators to guide and no psilocybin products to administer. It’s a classic chicken and egg scenario. It isn’t clear yet how many service centers will be licensed and operational by the end of the year and many facilitators may be without a job for longer than initially anticipated. “The service center to facilitator ratio may be out of whack for quite some time. So, facilitators will be forced to wait it out, apply for service center licenses of their own to address the bottleneck, or maybe even turn (or return) to the underground,” says Emerge attorney Kaci Hohmann.

 Other Noteworthy News

Psychedelics Could Revolutionize Couples Therapy
“Proponents of psychedelic use expect the U.S. Food and Drug Administration (FDA) to approve MDMA as a treatment for post-traumatic stress disorder (PTSD) within the next two years. If that happens, it could potentially open the door to other therapeutic uses of the drug—possibly including couples therapy. Research on MDMA in couples therapy is limited, but the practice has a long history. Some therapists legally used MDMA in couples counseling in the 1970s and 1980s. Effective as they can be, though, experts say it’s a mistake to think that psychedelics offer a one-way ticket to marital bliss.”
Vermont Legislators File Four Bills that Would Legalize Psychedelics and Decriminalize All Drugs
“Four major drug reform bills have been introduced in the Vermont State Legislature to decriminalize simple possession of all drugs, expand harm reduction services, remove criminal penalties for using and selling psilocybin and decriminalize certain psychedelic plants and fungi. Nearly a third of their 150-member House of Representatives have co-sponsored H.423, an all-drug decriminalization legislation sponsored by Reps. Logan Nicoll (D) and Taylor Small (P/D). Rep. Vyhovsky (P/D) has joined forces with ten other senators on the S.119 companion bill, making Vermont on its way to becoming the promised psychedelics land. H.439, sponsored by Rep. Brian Cina (P/D), would completely decriminalize psilocybin, mescaline and peyote in Vermont by removing them from Vermont's definition of hallucinogenic drugs. S.114 ,the other proposed bill by Sen. Martine Gulick (D) would not only remove the famed psilocybin mushroom from Vermont's drug classification, but also take an entire step above her colleague's effort to create a working group dedicated to studying the potential physical and mental health benefits of these substances. The specific psilocybin bill has been assigned to the Senate Health and Welfare Committee for deliberation, while all other related bills have been referred to their respective chamber's judiciary committee.”
Washington Senate Approves Scaled-Down Psilocybin Bill to Prepare State for Future Psychedelic Services
“The Washington State Senate has approved a bill to create a task force promoting research into psilocybin and developing a pathway for legal access to the psychedelic.
The legislation from Sen. Jesse Salomon (D)—which was effectively gutted in an earlier Senate committee to exclude original regulated access provisions—cleared the full chamber in a 41-7 vote on Tuesday. It now heads to the House. Senate Democrats cheered the passage, but advocates remain disappointed about the extent to which the bill was watered down in committee. That 81-page bill was reduced to an eight-page bill mandating the formation of a task force to explore regulatory pathways for the psychedelic in the future. It’s possible, of course, that House lawmakers may seek to further amend it in their chamber.”
Colorado’s Proposition 122: Too Soon for the Mushroom Boom?
“Is Colorado's passage of Prop. 122 a bridge too far for federal law enforcement? We have yet to see what the federal government's enforcement position will be with regard to legalizing magic mushrooms, much less DMT or Mescaline. Will the Department of Justice sit back and allow states to continue to legalize other Schedule 1 Controlled Substances without some federal interference? Alternatively, will Merrick Garland's Department of Justice issue a "mushroom memorandum" akin to the now-rescinded Cole Memorandum of 2013 for cannabis? As they say, history is often bound to be repeated. While Psilocybin may have a faster federal legalization trajectory than cannabis has, Colorado is wise to create a robust regulatory framework to stave off possible federal enforcement of the Controlled Substances Act. Industry participants need to understand the potential risks, and armed with a hefty dose of risk tolerance, seriously address compliance with state law. Is it too soon for a mushroom boom? We will have to wait and see.”
Vancouver Company Inks MDMA and Psilocybin Distribution Agreement in Australia
“Vancouver-based drug manufacturer and formulator Optimi Health has signed a distribution agreement to supply the Australian market with its MDMA formulation and psilocybin capsules. The products will be exported to Australia by July 1, 2023, when authorized psychiatrists can begin prescribing MDMA and psilocybin for specific mental health conditions. The distribution agreement is with Mind Medicine Australia (MMA), a leading charitable organization and patient advocacy group seeking to expand access to legal psychedelic-assisted therapies, and marks Optimi Health’s first international MDMA and psilocybin sale. All products destined for the Australian market will be manufactured, encapsulated and packaged inside Optimi’s facility under GMP-compliant protocols, and will follow Health Canada’s controlled substances export laws. To provide equitable access to its products, Optimi will allocate a percentage of product sales towards a fund managed by MMA to assist low-income earners and others who face systemic barriers to access, with those details to be announced in the coming weeks.”

Subscribe

Subscribe to PsychedeLinks to receive essential biweekly articles on news, business, and culture in the psychedelics industry, delivered straight to your inbox.

PsychedeLinks by Emerge Law Group
PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge Law Group’s groundbreaking Psychedelics Group.
Continue Reading
image title

CannaBeat – March 10, 2023

CannaBeat is a curated biweekly selection of top news stories impacting business, research, and culture in the cannabis industry, crafted by Emerge Law Group.

Emerge’s Hot Take

Emerald Triangle Communities Were Built On Cannabis. Legalization Has Pushed Them To the Brink

Legalization in California seemed like a dream come true for the cannabis industry, home of the Emerald Triangle. Abide by the rules and regulations in exchange for the opportunity to have a legal business. Six years later, and the price of cannabis is unbelievably low, businesses are closing, and the illegal market is flourishing. According to coverage by HighTimes and Forbes, cannabis sales declined in 2022, and many believe it wasn’t because people were consuming less.

The Emerald Tringle seems to be hit the hardest as cannabis is a base for much the community’s economy. Farmers in Humboldt reported that even though they sold all their product, they come in at loss for the year. Farm closures reverberate throughout Trinity County. Local businesses that depended on the patronage of the famers and their employees are laying people off and cutting hours. Some have lost so much revenue that they may close. In Mendocino, it is estimated that nearly 70% of operators might not remain in the legal market.

Besides overregulation, two major culprits are said to be the roots of the larger issues within the industry: high taxes and lack of shelf space. In attempt to fix the first problem, the State eliminated the cultivation tax in July of 2022. As for shelf space, 56% (302/539) of California jurisdictions still do not allow any type of commercial cannabis operations. There are only about 1000 licensed dispensaries serving 40 million residents. Delia Rojas of Emerge Law Group says that “the power local jurisdictions hold is frustrating, especially when residents of communities where a majority voted in favor of prop 64 haven’t experienced the product of their vote. Fear still runs rampant in much of the state. Education and advocacy continue to be important to wipe away the stigma surrounding this plant.”

Other Noteworthy News

Mendocino Growers Ask California To Address County’s Cannabis Licensing
A trade association representing cannabis growers in California’s Mendocino County has asked the state government for an “urgent intervention” in the county’s licensing process, citing concerns that many farmers’ license applications won’t be processed by a July 1, 2023, deadline. The Mendocino Cannabis Department and local government have failed to “establish a process capable of moving good-faith cannabis operators towards state annual licensure,” the Mendocino Cannabis Alliance (MCA) claims in a Feb. 8 letter to California Gov. Gavin Newsom and state Department of Cannabis Control Director Nicole Elliott. The letter charges that by the July deadline, the Mendocino Cannabis Department (MCD) will have licensed only 256 “prioritized” marijuana operators in the county, “implying that nearly 70% of Mendocino’s 841 current operators have no path forward to remain in the legal market,” according to an accompanying news release. “Further, among over 500 ‘deprioritized’ operators, MCA has found that a substantial number have been deprioritized incorrectly based on demonstrably false claims of tax delinquency or lack of state licensure.” MCA Executive Director Michael Katz said Mendocino County has “no functional permit program in Mendocino, and no plan to create one.”
Oklahoma Voters Reject Marijuana Legalization Ballot Initiative
Oklahoma voters have rejected a ballot initiative that would have legalized marijuana for adult use in the state on Tuesday. For most counties across the state, the cannabis reform measure—State Question 820—was the only proposal on the ballot, a unique scenario in the history of the legalization movement. Advocates tried to put the reform on the November 2022 ballot, but delays in signature verification by officials and the state Supreme Court’s subsequent decision in litigation meant that it missed the window to qualify for that cycle. In October, Gov. Kevin Stitt (R) called a special election for the cannabis measure that took place on Tuesday.
UConn Launches New Cannabis Cultivation Minor
The University of Connecticut announced a new minor in Cannabis Cultivation for students receiving specialized training in this growing field. “Since we launched the nation’s first cannabis horticulture course, UConn has been a leader in cannabis education and research,” says Indrajeet Chaubey, dean of the College of Agriculture, Health and Natural Resources. “We are thrilled to add another mechanism for students to formalize the skills, knowledge, and expertise in cannabis studies that they gain while at UConn.” Led by professors of plant science Gerald Berkowitz and Matthew DeBacco, the 15-credit minor was formalized in the spring 2023 semester. It provides training in the propagation, cultivation, commercial production, maintenance, processing, and potential markets for and uses of one species of cannabis, Cannabis sativa. As part of the minor, students can receive credit for approved internships with growers and companies to provide students with experiential learning opportunities and exposure to jobs.
Justice Department Website Opens Portal For Those Seeking Presidential Pardon Certificates
After a several month delay, the Justice Department has opened the online application process for those persons eligible to receive certificates indicating that their marijuana-related convictions have been pardoned by the President. The website began accepting applications hours after a notice published in the Federal Register stated that the Office of the Pardon Attorney had “developed the subject form to collect information from potential pardon recipients.” In its notice, the Office estimated that as many as 20,000 people may apply to receive pardon certificates.

Subscribe

Subscribe to CannaBeat to receive essential weekly articles on news, business, and culture in the cannabis industry, delivered straight to your inbox.

CannaBeat by Emerge Law Group
CannaBeat is a weekly brief on news, business, and culture in the cannabis industry curated by members of Emerge Law Group's distinguished Cannabis Industry Group.
Continue Reading
image title

DEA Takes a Rare Step Forward for Telehealth

Author: Matt Brockmeier, Emerge Of Counsel Attorney

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the Act) amended the Controlled Substances Act (CSA) to help prevent the illegal distribution of controlled substances on the internet. The Act required an in-person medical evaluation before prescribing or otherwise dispensing controlled substances online. It also established seven exceptions to that requirement, allowing practitioners to prescribe medications for a patient without first evaluating that patient in person. One exception allowed DEA to waive the in-person requirement during the COVID Public Health Emergency (PHE). During the pandemic several companies began providing large volumes of controlled substances via telehealth under that exception, including ketamine and Adderall. However, the exception it is set to expire on May 11, 2023, threatening the future of the nascent telehealth prescription industry.

Falling within the Act’s definition of the ‘‘practice of telemedicine’’ is ‘‘a practitioner who has obtained from the [DEA Administrator] a special registration under [21 U.S.C. 831(h)].’’ 21 U.S.C. 802(54)(E) contemplates that the DEA must issue regulations to effectuate this special registration provision. In 2017, under President Trump, DEA was statutorily instructed to finalize a rule on the registration’s application process and procedures. Disappointingly, as of this writing, DEA has yet to promulgate “special registration” rules, despite pleas from patients, clinicians, and the medical and business communities.

Analysts familiar with DEA’s intransigence and stall tactics predicted that the expiration of the PHE declaration would devastate the ketamine telehealth industry. In a surprise to most, including this author, on March 1 DEA issued a notice of rulemaking that would authorize telemedicine where 1) the prescribing practitioner has not conducted an in-person medical evaluation with the patient; 2) the prescription was issued pursuant to a telemedicine encounter and 3) the telemedicine encounter results in a prescription for controlled medications. There are some limitations, including that prescribing practitioners could only issue telehealth prescriptions for up to a 30-day supply, and there are labeling and recordkeeping requirements. Nonetheless, this is an encouraging development from an agency with a reputation for being dilatory and obstructionist, especially when it comes to making regulated medicines available to patients in need.

Continue Reading
image title

PsychedeLinks – March 3, 2023

PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge Law Group’s groundbreaking Psychedelics Group.

 Emerge’s Hot Take

DEA Proposes New Telemedicine Regulations
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the Act) amended the Controlled Substances Act (CSA) in an attempt to prevent the illegal distribution of controlled substances on the internet. Among other things, the Act required an in-person medical evaluation as a prerequisite to prescribing or otherwise dispensing controlled substances online. One exception allowed DEA to waive the in-person requirement during the COVID Public Health Emergency (PHE). During the pandemic a number of companies began providing a not insignificant volume of controlled substances via telehealth, namely ketamine and Adderall, subject to this exception. However, that exception is set to expire on May 11, 2023, thrusting a nascent industry into uncertainty over the past few months. Analysts familiar with DEA’s intransigence and stall tactics predicted that the ketamine telehealth industry would be devastated by the expiration of the PHE declaration. In a surprise to most, on March 1, 2023, DEA issued a notice of rulemaking that would authorize telemedicine where 1) the prescribing practitioner has not conducted an in-person medical evaluation with the patient; 2) the prescription was issued pursuant to a telemedicine encounter and 3) the telemedicine encounter results in a prescription for controlled medications. There are some limitations, including that prescribing practitioners will only be able to issue telehealth prescriptions for up to a 30-day supply of a controlled substance, and there are labeling and recordkeeping requirements. Some telehealth providers and advocates have concerns about some of the limitations in the DEA’s proposed rules, but for ketamine in general, “this is an encouraging development from an agency that has earned a reputation for being dilatory and obstructionist at times”, says Emerge Of Counsel attorney, Matt Brockmeier.

 Other Noteworthy News

Bill Seeks Personal Data Collection On People Who Use Legal Psilocybin in Oregon
“State Sen. Elizabeth Steiner, D-Portland, wants the state to monitor whether Oregon’s landmark law allowing the controlled use of psilocybin is working as intended — and not just for ‘rich white people.’ The Oregon Senate Health Committee on Monday heard her bill, Senate Bill 303, which would require psilocybin service centers to collect data on the health, education, race, income and other sensitive information of adults that use the hallucinogenic drug under their supervision. Steiner’s bill is in response to concerns that Oregon’s psilocybin program will only be accessible to those who can afford what could be hefty price tags service centers charge. It’s also meant to answer questions about the effectiveness of the first-of-its-kind program, which was pitched to voters as a means to address mental health and included a requirement that a report be issued on safety and efficacy after the first two years. Opponents of the bill argue it will mean another administrative burden that will further drive up the cost of psilocybin sessions. They also say its data collection requirement will have a chilling effect on people who may already be wary of using the federally illegal drug for its purported benefits.”
New Mexico Lawmakers Approve Psilocybin Study Bill
“New Mexico lawmakers advanced legislation on Wednesday to create a state body that would study the possibility of launching a psilocybin therapy program for patients with certain mental health conditions who could benefit from using the psychedelic. The House Health and Human Services approved the bill, sponsored by Rep. Christine Trujillo (D), in a unanimous voice vote. The measure now heads to the House Appropriations & Finance Committee. The legislation would establish an eight-member Psilocybin Advisory Group appointed by the governor that would be responsible for studying and making recommendations on the ‘feasibility’ of creating a psilocybin therapy program. Members would specifically need to consider policies to create a regulatory framework for psilocybin cultivation, manufacturing and dispensing, as well as ‘treatment guidelines for the use of psilocybin-derived products to treat certain mental health issues, including patient selection and provider training and certification.’”
More and More Psychedelic Reform Bills in the Pipeline Throughout United States
“2023 has already shown extensive advances in the realm of psychedelic policy reform. About a dozen states in the US have put forward legislation that would see multiple psychedelic substances from ketamine, MDMA, psilocybin, and more receive downgraded criminalization designations. In addition, lawmakers are as open as ever to the idea of psychedelics’ therapeutic potential. Special task forces or state-sponsored research bodies have been created or are set to be voted on which would seek to properly educate voters and state governing bodies on the possibilities associated with psychedelic therapy. With direct support from the Governor’s office, two new psychedelic research bills have been unanimously approved by Hawaii’s Senate Ways & Means Committee. While not exactly psychedelic policy, an important bill is brewing in Colorado’s state legislature. It would allow cities throughout the state to institute “overdose prevention centers”, similar to those seen in Europe, where citizens could use drugs regardless of their legality in a medically supervised environment.”
Untangling Anorexia: Psychedelics Offer Hope for a Neglected Condition
“Characterised by self-starvation, anorexia nervosa is a psychiatric disorder that mainly affects adolescent women, who become invested in restricting their food intake. A fear of weight gain can morph into a general fear of loss of control. In the past, clinicians have looked to pharmaceuticals for help, but several antidepressants, antipsychotics and nutritional or hormonal supplements have failed in clinical trials[4]. As a result, no medicine has been licensed. Another approach attempts to reset the outlook of a person with anorexia nervosa with psychedelics. Several clinical trials of psilocybin — the active ingredient in magic mushrooms — are underway. ‘If you experience that you can still have life, that you can still have hope, this helps to motivate the patient for further therapy,’ says Hubertus Himmerich, a clinician and researcher at King’s College London, who is leading a trial of psilocybin for anorexia, using ‘COMP360’ tablets of synthesized psilocybin manufactured by COMPASS Pathways. Two other trials of psilocybin therapy for anorexia nervosa are also ongoing.”

Subscribe

Subscribe to PsychedeLinks to receive essential biweekly articles on news, business, and culture in the psychedelics industry, delivered straight to your inbox.

PsychedeLinks by Emerge Law Group
PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge Law Group’s groundbreaking Psychedelics Group.
Continue Reading
image title

CannaBeat – February 24, 2023

CannaBeat is a curated biweekly selection of top news stories impacting business, research, and culture in the cannabis industry, crafted by Emerge Law Group.

Emerge’s Hot Take

Twitter Becomes First Social Media Platform To Allow Cannabis Ads In U.S.

On February 15, 2023, Twitter became the first major social media platform to remove their prohibition on the marketing and advertising of cannabis brands and products. Twitter’s announcement describes how they look to expand the opportunities for one of the most influential markets that utilizes its platform for the exchange of ideas, experiences, and overall business development. Naturally, the new opportunity comes with a list of rules and restrictions which can be found on their updated Cannabis Ad Policy. For example, the cannabis business must have the proper license, prohibit targeting anyone under 21, must not use characters, celebrities, or other icons appealing to minors, and can only target jurisdictions where they are legally allowed to operate. The most restrictive and slightly counter-intuitive rule states “advertisers may not promote or offer for sale of cannabis.” This could prove difficult to navigate but not impossible.

Even with these restrictions, Emerge Attorney Delia Rojas believes that “cannabis businesses will seize this opportunity while most other large social media competitors still flat out ban cannabis advertising and deactivate accounts.” It is unquestionable that social media plays a huge role in any businesses’ advertising plan. Forbes reported that some estimate 20 million tweets about cannabis topics were posted in the past year. With 37 states passing some form of cannabis regulatory structure, and more states looking to join the club in 2023, this is a long overdue and applauded step forward.

Other Noteworthy News

WA Senate Passes Bill to Bar Hiring Discrimination For Cannabis Use
Washington employers would be prohibited from refusing to hire a potential worker solely because of a drug test showing they had used cannabis under a bill that passed the state Senate on Wednesday. Washington voters approved recreational marijuana in 2012 through Initiative 502. More than a decade later, though, as more states have moved to legalize the drug, Washington employers can still screen out applicants who use cannabis. If Senate Bill 5123 becomes law, Washington would join several other states that have enacted laws shielding employees from workplace penalties for off-duty cannabis use. The bill passed the state Senate on a 28-21 vote Wednesday, sending it to the House for further consideration. In 2019, Nevada became the first state to stop employers from rejecting an applicant because of a drug test showing cannabis use. Last year, California Gov. Gavin Newsom signed into law a bill barring discrimination in hiring, firing and other conditions of employment if a worker uses cannabis while off duty.
Legalized Marijuana Proposal Unveiled By Iowa Democrats
Marijuana would be legal for recreational use, previous convictions for non-violent possession charges would be removed from an individual’s criminal record, and the state’s medical cannabis program would be expanded under legislation introduced Tuesday by Democratic state lawmakers. The proposal is not likely to become state law any time soon, since Republican state lawmakers in leadership and Gov. Kim Reynolds have in the past opposed any efforts to legalize marijuana in Iowa. Nationally, 21 states have legalized recreational marijuana, including Iowa neighbors Missouri and Illinois. Minnesota state lawmakers are considering legislation to legalize marijuana there. “It is time,” said Iowa Rep. Jennifer Konfrst, a Windsor Heights resident and leader of the minority-party House Democrats. Konfrst argued that legalizing marijuana would keep sales tax revenue in Iowa instead of sending it to other states, it would preserve state resources that currently go toward enforcing marijuana laws, and it would increase the quality of life for Iowans with chronic illnesses.
North Carolina Senate Panel Approves Medical Marijuana Bill
A North Carolina legislative committee on Tuesday approved a bill that would legalize medical marijuana in the state. The measure, known as the North Carolina Compassionate Care Act (Senate Bill 3), was approved by the Senate Judiciary Committee with little debate among senators, according to media reports. The bipartisan bill was filed on January 25 with sponsorship from Republican Sens. Bill Rabon and Michael Lee and their Democratic colleague Sen. Paul Lowe. If passed, the bill would legalize the medicinal use of cannabis for patients with one or more specified qualifying serious medical conditions such as cancer, ALS, Parkinson’s disease, epilepsy, multiple sclerosis, post-traumatic stress disorder and others. Unlike the more comprehensive medical marijuana programs in many other states, however, the bill does not authorize the use of medical marijuana by patients living with chronic pain.
Delta-8 Brouhaha Creates Marijuana Opportunity In Next Federal Farm Bill
If Congress can’t (or won’t) bundle marijuana reform with the F-35 fighter jet and nuclear submarines, why not food stamps and corn subsidies? Among the pressing items on federal lawmakers’ 2023 to-do lists is renewing the Farm Bill. Every five years, the sprawling, multipart, $428 billion monster that deals with nutrition and rural development as well as what American farmers grow and how they grow it is revamped. And the 2018 Farm Bill that legalized hemp and triggered the boom in delta-8 THC and other intoxicating hemp-derived cannabinoids expires in September. Federal marijuana prohibition means the American cannabis industry still exists separately from federal farm programs and the U.S. Department of Agriculture. Despite this, and despite the many other loud and needy lobbies competing for attention, there’s a growing push in Washington DC for Congress to consider marijuana reform during Farm Bill discussions, according to multiple lobbyists and a federal lawmaker who spoke with MJBizDaily.
The Cannabis Experience Becomes First Marijuana-Licensed Consumption Bus
The Cannabis Experience in Denver has become Colorado's -- and the nation's -- first marijuana-licensed consumption bus. As the cannabis industry continues its blazing trail, local marijuana users can enjoy safe, legal cannabis tours, airport transportation and private cannabis-friendly party buses. The Cannabis Experience will offer transportation services to Denver International Airport along with private party bus rentals with food and art themes such as "Toking and Tacos," and "RiNo Mural Tours." The service also provides tours of the city and tourist attractions. "The Cannabis industry is extremely regulated and not diverse. It took us almost a year to become operational, so we are excited to be the country's first safe, legal, licensed mobile hospitality business," Sarah Woodson said. "We are social equity and African American. We will have amazing tours, and grow our fleet over the next 24 months and work on expanding into other local cities such as Aurora. We are helping move the needle forward in the legalization fight. We are proud to be in the cannabis industry." Visits to cannabis grows and dispensaries are also included in the services as bookings are being accepted now for the grand opening, which is set for March 1.

Subscribe

Subscribe to CannaBeat to receive essential weekly articles on news, business, and culture in the cannabis industry, delivered straight to your inbox.

CannaBeat by Emerge Law Group
CannaBeat is a weekly brief on news, business, and culture in the cannabis industry curated by members of Emerge Law Group's distinguished Cannabis Industry Group.
Continue Reading
image title

Critical Terms for Intellectual Property License Agreements (Part 2)

Author: Sean Clancy

An audit provision is a clause in an intellectual property license agreement that provides the right for the licensee (the party receiving the license) or the licensor (the party granting the license) to inspect the records of the other party to verify compliance with the terms of the agreement. This provision is included in intellectual property license agreements to ensure that both parties are complying with the terms of the agreement.

One common reason for an audit is to ensure that the licensee is paying the correct royalty fee. The license agreement will typically specify the amount of royalties that the licensee must pay for the use of the intellectual property. An audit provision gives the licensor the right to inspect the licensee’s records to ensure that the correct royalty fees are being paid. This helps to prevent the licensee from underreporting the amount of royalties owed, which would be a breach of the agreement.

Another reason for an audit is to ensure that the licensee is using the intellectual property in accordance with the terms of the license agreement. For example, if the license agreement restricts the use of the intellectual property to a certain geographic area or market segment, an audit provision can help to ensure that the licensee is not using the intellectual property outside that area. This helps to prevent unauthorized use of the intellectual property.

In addition to protecting the interests of both parties, an audit provision can also help to avoid disputes that may arise under the license agreement. For example, if the licensee disputes the amount of royalties owed, an audit provides a legal right for licensee to review royalty reporting without resorting to a lawsuit. Similarly, if the licensor believes that the licensee is using the intellectual property outside the terms of the agreement, an audit can provide evidence about whether or not a violation is occurring.

It is also important to consider limitations on the use of the audit provision. For example, the audit provision may specify that audits can only be conducted during business hours and with reasonable advance notice. Additionally, the frequency of audits may be limited to prevent excessive intrusion into the licensee’s business.

An audit provision is another critical component of an intellectual property license agreement. It provides a means for verifying compliance with the terms of the agreement, resolving disputes, and preventing unauthorized use of the intellectual property. The inclusion of an audit provision in an intellectual property license agreement helps to protect the interests of both parties and ensures that the license agreement is properly enforced.

Continue Reading
image title

PsychedeLinks – February 17, 2023

PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge Law Group’s groundbreaking Psychedelics Group.

 Emerge’s Hot Take

Lawmakers Could Limit Personal Psychedelic Rights Created by Prop 122
There’s been chatter coming from Colorado this week that lawmakers will move forward this session with legislation restricting the Natural Medicine Health Act (“NMHA”). The NMHA is a rather broad act with a decriminalization element allowing personal use, possession, cultivation, and adult sharing of five psychedelic medicines (psilocybin, psilocin, mescaline (excluding peyote), DMT, and iboga), and a regulated element allowing adult consumption at state-licensed healing centers. At a Boulder town hall meeting on February 13, 2023, Colorado Senator Steve Fenberg confirmed the Colorado legislature will consider specific limitations on cultivation, possession, and transportation restrictions for the decriminalization component of the NMHA. Other groups in Colorado are lobbying for local jurisdiction approval of cultivation and healing centers. Colorado is home to a growing and vibrant community of advocates and activists who are working tirelessly to ensure the healing potential of these medicines is fully realized. “In the months before the election, psilocybin advocates who supported decriminalization before commercialization voiced concerns that legislators would water down the hard-won ‘personal use’ provisions. It appears those fears have just been substantiated. It would be paternalistic and antidemocratic for legislators to defy constituents by substantially modifying the law at this point,” says Matt Brockmeier, Of Counsel Attorney at Emerge Law Group.

 Other Noteworthy News

Australian Approval of MDMA and Psilocybin a ‘Baby Step in the Right Direction’, Medical Experts Say
“The Therapeutic Goods Administration announced on Friday that, from July, approved psychiatrists would be able to prescribe MDMA (ecstasy) for post-traumatic stress disorder and psilocybin (found in magic mushrooms) for treatment-resistant depression. The move makes Australia the first country in the world to officially recognize psychedelics as medicines. Psychiatrists will need to get approval by a human research ethics committee, then approval under the TGA’s authorized prescriber scheme. To get those approvals they must demonstrate their training, robust patient selection and evidence-based treatment protocols, as well as patient monitoring. They must also satisfy governance and reporting criteria. Because there are are currently no approved Australian substances, the psychiatrist would also have to apply for a license to import them.”
Psychedelics May Be Part of U.S. Medicine Sooner Than You Think
“In Nov. 2022, the U.S. nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) announced that it had completed a second phase-three trial on MDMA as a treatment for PTSD—a step widely seen as the last hurdle to clear before applying for approval from the U.S. Food and Drug Administration (FDA). Rick Doblin, MAPS’ founder and executive director, says his group is preparing to apply for FDA approval based on those data. If all goes well, he says, the drug could be approved as soon as 2024. Australia’s approval of these drugs, Doblin says, may only expedite the approval process in the U.S. A representative for the FDA did not respond to TIME’s request for comment before press time. But in a May 2022 letter first published by the Intercept, a U.S. Department of Health and Human Services official wrote that FDA approval of MDMA and psilocybin was ‘anticipated’ within ‘approximately 24 months.’”
Arizona Lawmakers Unanimously Approve Bipartisan Psilocybin Research Bill
“Arizona lawmakers have approved a bill in committee to promote research into the medical potential of psilocybin mushrooms for a variety of conditions, which could inform future reforms to more broadly allow access to psychedelic-assisted therapy. The proposal is focused on psilocybin research, providing $30 million in grants over the course of three years for scientists to study the impact of the psychedelic on 13 different conditions such as post-traumatic stress disorder (PTSD), depression, anxiety, long COVID symptoms and substance misuse disorder. The research grants would be appropriated for phase I, II and III clinical trials that are “capable of being approved by the United States Food and Drug Administration (FDA) to evaluate the effects of whole mushroom psilocybin” for the designated conditions. A “Psilocybin Research Advisory Council” would be established under the Department of Health Services (DHS), tasked with establishing eligibility criteria for grant recipients, overseeing applications and making “recommendations to the governor, the speaker of the House of Representatives, the president of the Senate and the department on psychedelic-assisted therapy based on current federal and state research policy.”
Senator Pivots to Pilot Program to Legalize ‘Magic Mushrooms’ in Utah
“A lawmaker is paring down her plan to decriminalize magic mushrooms in Utah for patients suffering from certain conditions. Senate Bill 200, sponsored by Sen. Luz Escamilla (D-Salt Lake City), now aims to create a pilot program for patients to use psilocybin. She hopes that change might move it across the finish line. Escamilla’s plan would allow patients suffering from depression, anxiety, PTSD, or those on hospice care to use psilocybin. But it would cap the number of patients at 5,000. ‘This will be under a lot of control,’ said Escamilla. Her bill would also impose an end date to the pilot program so the Legislature can review it.”

Subscribe

Subscribe to PsychedeLinks to receive essential biweekly articles on news, business, and culture in the psychedelics industry, delivered straight to your inbox.

PsychedeLinks by Emerge Law Group
PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge Law Group’s groundbreaking Psychedelics Group.
Continue Reading
image title

CannaBeat – February 10, 2023

CannaBeat is a curated biweekly selection of top new stories impacting business, research, and culture in the cannabis industry, crafted by Emerge Law Group.

Emerge’s Hot Take

North Bay Cannabis Operators Back California Bill to Allow Food and Music at Dispensaries

A bill has been introduced in California that would allow a retailer to offer a similar experience as a local venue or cafe (Assembly Bill 374). Retailers with approved consumption lounges could offer the sale of non-cannabis infused foods, non-alcoholic beverages, and tickets to live music. This would be comparable to general venues, providing the cannabis space with equal opportunity for tourism and potentially “nightlife.”  Furthermore, allowing for larger or more inclusive events would permit for further educational platforms and work to promote the industry in a positive way. There are other events such as music festivals that have included these types of platforms such as Outside Lands in San Francisco (see “Grass Lands”). This bill would allow smaller and similar events accessible to the local community.

Although the bill looks to expand opportunity, whether or not it will do so is unknown. As written, the proposed bill states that “a local jurisdiction may allow the retailer or microbusiness….” This would leave the decision up to the local governments which has proven difficult in California (56% of jurisdictions do not allow any type of commercial cannabis operations, as shown HERE). California Emerge attorney Delia Rojas commented: “Given the tough market, I could foresee certain jurisdictions being open to these types of consumption lounge models, but the bill will likely receive the same local government pushback as similar past bills.”

Other Noteworthy News

GOP Congressman Files Marijuana Rescheduling Bill Amid Ongoing Biden Administration Review
A GOP congressman has refiled a bill to move marijuana from Schedule I to the less restrictive Schedule III under federal law. Rep. Greg Steube (R-FL) introduced the proposal on Friday. This is the third session in a row that he’s pushed for the modest reform, titled the “Marijuana 1-to-3 Act.” The two-page bill states that “the Attorney General of the United States shall, by order not later than 60 days after the date of enactment of this section, transfer marijuana…from schedule I of such Act to schedule III of such Act.” Advocates are strongly pushing for removing cannabis from the Controlled Substances Act (CSA) altogether, but the congressman has argued that rescheduling could be an interim move to promote research into the plant and its components. “As marijuana is legalized for medical and recreational use across the United States, it is important that we study the effects of the substance and the potential impacts it can have on various populations,” he said in 2019. “By rescheduling marijuana from a schedule I controlled substance to a schedule III controlled substance, the opportunities for research and study are drastically expanded.”
Gun Ban for Marijuana Users Is Unconstitutional, U.S. Judge Rules
The ban on gun ownership for marijuana users in Oklahoma has been declared unconstitutional by a federal judge, as it violates the Second Amendment right to bear arms. U.S. District Judge Patrick Wyrick, on February 3, declared that an indictment against a man charged in August for violating a firearms ban was dismissed as it violated the Second Amendment of the U.S. Constitution. Jared Michael Harrison was taken into custody by Lawton police, Oklahoma, in May 2022 during a routine traffic stop. The search of his car uncovered a loaded revolver and marijuana. Harrison informed the officers that he was heading to his job at a medical marijuana dispensary but lacked the mandatory state-issued medical marijuana card. Harrison's lawyers argued that their client's Second Amendment right to bear arms was violated by a federal law prohibiting "unlawful users or addicts of controlled substances" from possessing firearms. They claimed the law, focused on drug users or addicts, was inconsistent with the historical tradition of firearms regulation, citing the U.S. Supreme Court's ruling in the New York State Rifle & Pistol Association v Bruen case, which set new standards for interpreting the Second Amendment. In contrast, federal prosecutors argued that the law, focused on disarming drug users, is consistent with the longstanding tradition in America of disarming "presumptively risky persons" such as felons, the mentally ill, and the intoxicated.
The Lexi to Become First “Cannabis Friendly” Hotel in Vegas
Coming to the Las Vegas Strip this spring, the Lexi seeks to offer a ‘cannabis-forward’ hospitality experience – and topless sunbathing. Rose Dykins reports. Following a multimillion-dollar renovation, the Artisan Hotel Boutique in Las Vegas is reopening as the Lexi, a fun-loving property that embraces cannabis-friendly hospitality. Owned by Elevations Hotels and Resorts, the Lexis is the first of its kind in Vegas. Situated moments from the Vegas Strip, the property has 64 all-new rooms, with its fourth floor designated as cannabis-friendly. A “cheeky” hotel concept that seeks to normalise cannabis in travel, the Lexi will also offer a high-end experience, an exciting culinary and cocktail offering and a season of spring-summer pool party events. The Lexi’s Cajun-inspired steakhouse will be overseen by executive chef Jordan Savell of Hell’s Kitchen fame.
Mint to Host 3-Day Cannabis Party Near State Farm Stadium for Super Bowl
Mint Cannabis will be holding a “Big Game” party with a three-day festival near State Farm Stadium in Glendale during Super Bowl weekend. The Arizona-based company’s Cannabis Consumption Park will be similar to how a beer garden is run, offering activities, infused foods, cannabis vendors with complimentary samples, live musical performances, comedy skits, celebrity appearances and more for people ages 21 and up, according to a press release. Located off 99th Avenue and Thomas Road, the “Mint Mall” will feature many leading cannabis brands for guests to sample. It will run from Feb. 10-12. “Having a cannabis-friendly celebration at the nation’s biggest sporting event of the year is a big testament to how far our industry has evolved in a relatively short time,” cofounder and CEO Eivan Shahara said in the release. “Our large setup will be a reflection of our five dispensaries in the Valley, where our expert budtenders cater to the needs of medical patients, experienced recreational users, and curious first-timers.” At 4:20 p.m. on Saturday, 10,000 complimentary pre-rolls will be lit in an attempt to break the Guinness Book record for the World’s Largest Smoke Session, followed by a live concert.
Subscribe to CannaBeat by Emerge Law Group
CannaBeat is a curated biweekly selection of top news stories impacting business, research, and culture in the cannabis industry, crafted by Emerge Law Group, delivered straight to your inbox. Click here to subscribe!
Continue Reading
image title

Trademark applicants – beware spoofed calls that impersonate the USPTO

Scammers have recently started calling trademark customers and falsely claiming to be an employee with the United States Patent and Trademark Office (USPTO). The scammers use a tactic called “spoofing,” where they trick phone networks into displaying a fraudulent name, number, and location. They’re trying to trick you into believing you’re talking to the USPTO, so they can steal money or personal information from you.

If you receive a call from someone you suspect is a scammer, do not give them any personal identifying or payment information. The USPTO will never ask for your personal or payment information over the phone.

If you ever have questions about the status of trademark applications or your trademark rights, reach out to Emerge Law Group intellectual property practice group chair, Sean Clancy.

Continue Reading
image title

PsychedeLinks – February 3, 2023

PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge Law Group’s groundbreaking Psychedelics Group.

 Emerge’s Hot Take

Regulatory Hurdles Challenge Oregon Psilocybin Providers
Emerge attorneys, Dave Kopilak and Kaci Hohmann, are quoted in this Lucid News article along with other key individuals in the Oregon psilocybin services world. Ranging from insurance to land use to business realities, the article touches on the primary legal concerns facing prospective psilocybin business owners. In a public records request, the Oregon Health Authority disclosed that as of January 27, 2023, applications have been submitted for 6 manufacturer licenses, 3 service center licenses, and 1 laboratory license. These numbers reflect the contemplative approach that many prospective psilocybin business owners are taking in Oregon. As we progress through the year, we anticipate a moderate surge in license applications. Until then, we just have to wait to see how things shake out. As Dave mentions in the article, there is a concern that there may be too many facilitators and not enough service centers, at least at the outset. “I hope it will eventually stabilize into a sustainable, thriving ecosystem,” he says.

 Other Noteworthy News

Psychedelics Bills Filed in Four More States as 2023 Reform Efforts Heat Up
“Another series of psychedelics reform bills have been introduced in states from New Hampshire to Hawaii, building on the movement that’s seen exceptional activity in the 2023 session. Sen. Ron Kouchi (D) [in Hawaii] filed a bill to create a “therapeutic psilocybin working group” that would be tasked with studying the “medicinal and therapeutic effects of psilocybin or psilocybin-based products” for conditions such as anxiety, depression and post-traumatic stress disorder (PTSD). The body would also need to look into the efficacy of therapeutic psilocybin programs that are being implemented in Colorado and Oregon. A bill from Rep. Matthew Santonastaso (R) [in New Hampshire] would simply remove the psychedelic DMT from the list of controlled substances under state statute. A Republican New Hampshire lawmaker also recently filed a bill to legalize the possession and use of psychedelics like psilocybin and LSD by adults 21 and older. Sen. Nathalia Fernandez (D) [in New York] has filed a bill to legalize psilocybin therapy for patients with qualifying conditions. Under the proposal, people could receive psilocybin treatment from a certified facilitator in a clinical setting, or at their home if they’re unable to travel. In Utah, Senate Minority Leader Luz Escamilla (D) has announced plans to soon file legislation to legalize psilocybin for people with serious mental health conditions. In West Virginia, Rep. Kayla Young (D) filed a bill that would simply remove psilocybin, marijuana and THC from the state’s list of controlled substances.”
Colorado Appoints Natural Medicine Advisory Board to Share Psychedelic Program
“On Friday, Governor Jared Polis announced members of the Colorado Natural Medicine Advisory Board. This fifteen-member board sits within the Department of Regulatory Agencies (DORA), where it will advise regulators drafting rules for the state’s psilocybin program. The board consists of two types of appointees. The first group will serve two-year terms, and the second will serve four-year terms. All but one of the appointed members reside in Colorado. At least on the surface, few board members appear to have experience directly related to psychedelics. Several board members have experience related to drug policy or substance use treatment.”
Senator to Present Medical Hallucinogens Legalization Bill
“A senator with the Ecological Green Party of Mexico (PVEM) has committed to presenting a bill to legalize and regulate natural hallucinogenic substances such as psilocybin for the treatment of mental health problems such as depression and anxiety. The PVEM senator told forum attendees — among whom were indigenous leaders, traditional healers and scientists — that in Mexico’s indigenous towns, there is ‘infinite wisdom and knowledge about psilocybin mushrooms and what they can do for people’s mental health.’ There has been a “prohibitionist policy” on natural hallucinogens since the 1960s, and the General Health Law considers such substances as ‘psychotropic with no therapeutic value’ and a ‘problem for public health,’ she added. The senator said that several countries have decriminalized substances such as psilocybin to treat mental health disorders and it’s ‘urgent’ for Mexico to do the same.”
Baylor Launches Program Focused on Bioethics and Health Policy of Psychedelics Research
“Research into the medical use of psychedelics to treat mental health is on the rise, but the impact of this research remains unclear. To address questions around this issue, the Center for Medical Ethics and Health Policy at Baylor College of Medicine is launching a new program to explore Ethical and Legal Implications of Psychedelics In Society (ELIPSIS). As part of the new program, experts will outline policies and ethical guidelines for psychedelic research, examine legal implications of psychedelic use for medical care, measure psychosocial impacts of psychedelic research and help to train the next generation of scholars interested in ethical and policy issues related to psychedelics. A multidisciplinary team of experts in bioethics, social science, medicine, health policy and law will study the ethical legal and social implications of this research.”

Subscribe

Subscribe to PsychedeLinks to receive essential biweekly articles on news, business, and culture in the psychedelics industry, delivered straight to your inbox.

PsychedeLinks by Emerge Law Group
PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge Law Group’s groundbreaking Psychedelics Group.
Continue Reading

FRANCHISE LAW

Franchisors

Franchise law is a heavily regulated area of law.  We help clients expand their businesses through franchising and other distribution methods. We have experience in many industries including, restaurants, health, and beauty, alcohol, and cannabis among others. Our representative services include the following:

Franchisees

We also help potential franchisees interested in buying a franchise. We are able to assist with evaluation of franchise opportunities with respect to:

Alternative Structures

However, not all businesses are suited to franchise. We are also experienced with helping clients structure alternative distribution methods to prevent classification as a franchise.

MERGERS AND ACQUISITIONS

Our M&A attorneys are highly experienced in counseling clients who are considering acquisitions or exit strategies.  We have many years of experience handling deals of various types and sizes, ranging from sales of small closely-held business, private companies, and publicly-traded corporations.  We have represented business owners, private equity firms and investment banks in a wide range of industries. 

We have a deep business bench, and Emerge attorneys have handled transactions of all shapes and sizes.  Whether your deal is valued at $100,000 or $100,000,000, our experienced attorneys will guide you through the deal process.

We understand the intensity, technical skill and judgment needed to get deals done, and we provide our clients with timely, practical and cost-effective legal advice.  We are highly capable in all aspects of M&A, including the following:

CANNABIS INDUSTRY

Emerge Law Group is highly experienced in the cannabis industry.  We have helped many clients obtain state licenses and local permits to operate cannabis businesses throughout California, Oregon, and Washington.

Emerge attorneys were instrumental in the drafting and passage of Oregon Measure 91, legalizing marijuana in the State of Oregon, and have represented cannabis businesses well before many law firms were willing to enter the cannabis industry. As a firm that has provided legal services in the cannabis space for many years, we are familiar with the unique and complex issues businesses and individuals face in an emerging and highly regulated industry.

We regularly help clients with:

Cannabis laws and rules are also regularly changing.  Members of our team are dedicated to attending legislative hearings, state agency and local city and county meetings to stay up-to-date on any new changes and how to adjust to any new changes.

See our Cannabis Industry page for more information.

PSYCHEDELICS

There is tremendous excitement about the potential for psychedelic drugs to benefit a wide variety of populations, including terminally ill patients suffering with anxiety and depression. Until recently, psychedelic substances have been accessible only in the illicit market and are illegal under federal and state to manufacture, distribute, or possess. These substances have, since 1970, been treated as having no legitimate medical use, and no commercial application. As such, no one invested in this area or required legal services, outside of the criminal context.

Today, researchers in a multitude of clinical studies are proving the medical safety and efficacy of these medicines, with the objective of changing the treatment of these substances under the Controlled Substances Act. Companies are now actively raising money to develop intellectual property and seize market opportunities associated with psychedelic drugs.

In addition, advocates at the state and local levels are not waiting for the rescheduling of these substances and are active in undertaking efforts to decriminalize these substances and/or make them affirmatively legal under state and/or municipal law. Decriminalization already has occurred in cities including Denver, Oakland, Santa Cruz, and Ann Arbor. Oregon is poised to be the first state to make psilocybin therapy affirmatively legal. Emerge Law Group is working with a wide array of clients pushing forward in this emerging area.

See our Psychedelics Practice Group page for more information.

TAXATION

CORPORATE AND PARTNERSHIP TAX

Businesses of all kinds benefit from a customized but systematic approach to structuring legal relationships. Emerge Law Group helps businesses and business owners with a variety of tax planning matters.

Representative client services include:

ESTATE PLANNING

Estate planning encompasses everything from a will and power of attorney to combined estate and business succession planning. In almost all cases, the purpose of the plan is to help the client protect those they care about most in the event they can no longer be there for them.

Emerge Law Group has experience with a wide range of tools used in estate planning, including wills, trusts, and family business entity planning.

TAX CONTROVERSIES

Emerge Law Group can assist with the resolution of difficult tax controversies. Our areas of emphasis and experience include:

REAL ESTATE TRANSACTIONS

Emerge Law Group assists clients with a wide range of real estate transactional matters.  We regularly help clients with:

LAND USE

Emerge Law Group also assists clients with all aspects of local government land use and development processes, ranging from preliminary property analyses and building permit issues to complex land use reviews and hearings. Our attorneys are experienced in obtaining land use entitlements and development permits for a wide range of uses.

We regularly help clients with:

Above all, we understand the value of working with cities and counties to enhance communities while developing the land to its potential. We strive to create solutions to land use issues that serve to better our clients and the communities in which they live and work.

LITIGATION AND ALTERNATIVE DISPUTE RESOLUTION

The attorneys in Emerge Law Group’s Litigation and Alternative Dispute Resolution practice group litigate commercial, intellectual property, and public interest matters in state and federal courts, as well as private mediation and arbitration proceedings.  Our lawyers have represented national and regional financial institutions, major media, entertainment and technology companies, and other Fortune 500 companies in a broad array of high-stakes disputes.  Our team of litigators has handled leading cases that have shaped the law in cutting-edge business, technology, free speech, and public interest impact lawsuits in trial and the courts of appeal.

We have particular expertise in handling civil litigation and regulatory enforcement matters in the cannabis and psychedelic industries.  While many firms claim expertise in the these industries, few have our depth of experience successfully litigating contract, trademark, partnership, shareholder, land use, and real estate disputes in court and arbitration.  Even fewer firms have our level of experience handling writ of mandate proceedings against the government regulators.

Our litigators practice in California, Oregon, and Washington, but have appeared in state and federal courts nationwide.  Our knowledge of our clients’ businesses, goals and concerns, and our experience litigating at the highest levels, give us unique insight into possible outcomes and pitfalls as we continuously confront issues of new impression.

No matter what the industry, we pride ourselves in achieving our clients’ objectives through efficient and creative solutions primarily designed to avoid disputes in the first place—which is always the best litigation strategy.  Many times, our clients obtain excellent outcomes before or at the earliest stages of litigation because our adversaries quickly recognize the challenges they will face in litigating against us.  When litigation is unavoidable, however, we work hard to provide our clients with both cost-efficient and “big firm” quality representation.

 

INTELLECTUAL PROPERTY

Your intellectual property (or “IP”) strategy can harness your most valuable information and intangible assets including your name, your brand, your designs, your content, your services, and your products — what makes your business stand apart in a competitive world.  We can help you evaluate and build your IP portfolio, then secure it, monetize it, and protect it.

IP encompasses multiple areas of law and different types of information or material.

Our Intellectual Property practice focuses on:

TRADEMARK

Trademarks include names, signs, logos, designs, phrases, slogans, expressions, and sometimes even colors, sounds, or smells that identify or distinguish one business compared to others.  Trademark protection is fundamental in securing your “brand.”

COPYRIGHT

Copyright covers original works of creative authorship fixed in a tangible medium of expression.  This includes literary, dramatic, musical, and artistic works, such as poetry, novels, designs, movies, songs, computer software, and architecture. Copyright does not protect facts, ideas, systems, or methods of operation, although it may protect the way these things are expressed.  Depending upon the type of work, “moral rights” (such as the right of attribution) may be implicated as well.

TRADE SECRET

Trade secret laws can vary somewhat between states, but generally trade secrets cover information, including drawings, cost data, customer lists, formulas, recipes, patterns, compilations, programs, devices, methods, techniques or processes that derive economic value from not being generally known and are the subject of efforts that are “reasonable under the circumstances” to maintain secrecy.

PRIVACY

Depending upon where you live or operate, there is a special patchwork of laws and regulations that protect and regulate personal information.  If you are handling or giving out personal or potentially sensitive information, you may be implicating privacy laws.

PUBLICITY

Publicity rights address the commercial use of an individual’s face, name, image, or likeness.  These rights vary state-to-state.  Marilyn Monroe, for example, lived in multiple states which created complex questions about her publicity rights.

Our Intellectual Property services include:

FINANCIAL INSTITUTIONS

In states where new cannabis banking opportunities exist, Emerge Law Group has the proven expertise in creating canna-banking programs to efficiently capitalize on those opportunities. Our Banking Practice Group specializes in working with banks and credit unions to develop regulatory compliant programs and operational best practices. We also train banking staff to become experts in canna-banking so they can effective understand and manage the risk affiliated with canna-banking.

We regularly help clients with:

EMPLOYMENT LAW

At Emerge Law Group, we recognize that employees are the heart and soul of any successful business.  Our Employment Law Practice Group works with employers to help them effectively manage their workforce, navigate the complex web of federal, state and local employment laws and, if necessary, defend against claims before administrative agencies and in court.

We regularly help clients with:

CORPORATE FINANCE AND SECURITIES

Our corporate finance and securities lawyers are experienced attorneys who have practiced at large law firms, worked as in-house counsel for public companies and investment banks, and owned and operated start-up companies. We work with clients to help achieve their financing goals while safely navigating the highly technical securities law landscape. 

In addition to representing issuers, we also routinely represent institutional and individual investors, including in connection with fund formation and investments.

Our expertise includes:

We have a deep understanding of the financing options available to businesses, including simple unsecured loans, asset-backed financing, convertible debt, common and preferred equity, crowdfunding and various other structures.  We work closely with our clients to understand their business and financing needs, ensure they are prepared to approach investors and choose the right partners, structure and negotiate terms, navigate the due diligence process and successfully close the deal.

COMPLIANCE AND LICENSING

ALCOHOL AND BEVERAGE INDUSTRY

Emerge attorneys have represented businesses in the alcohol and beverage industry, including wineries, breweries, distilleries, restaurants, bars, movie theaters, golf courses, and gas stations.  We can help you vet new locations, acquire existing locations, and apply for the appropriate liquor license.  We also provide training to comply with applicable rules and regulations, prepare operating procedures, submit renewals, and keep clients protected in the event of any potential violations or administrative hearings.

CANNABIS INDUSTRY

Emerge Law Group is highly experienced in the cannabis industry.  We have helped many clients obtain state licenses and local permits to operate cannabis businesses throughout California, Oregon, and Washington.  We regularly help clients with:

Cannabis laws and rules are also regularly changing.  Members of our team are dedicated to attending legislative hearings, state agency and local city and county meetings to stay up-to-date on any new changes and how to adjust to any new changes.

See our Cannabis Industry page for more information.

PSYCHEDELICS INDUSTRY

Emerge Law Group is a leader in the psychedelics industry.  There is tremendous excitement about the potential for psychedelic drugs to benefit a wide variety of populations, including veterans struggling with PTSD and terminally ill patients suffering with anxiety and depression.  Until recently, psychedelic substances have been accessible only in the underground; they are illegal under state and federal law to manufacture, distribute, or possess.  These substances have, since 1970, been treated as having no legitimate medical use, and no commercial application.  As such, businesses have not invested in this area or required legal services, outside of the criminal context.

Today, psychedelics are proceeding toward legalization on multiple paths.  Researchers in a multitude of clinical studies are proving the medical safety and efficacy of these medicines, with the objective of changing the treatment of these substances under the federal Controlled Substances Act, opening legal access to them.  Private and public companies are now actively raising money to develop intellectual property and capitalize on the market opportunities associated with psychedelic drugs.  Opportunities to be early actors in this new arena are tremendous.

See our Psychedelics Practice Group page for more information.

BUSINESS AND CORPORATE

Our business transactions team is made up of highly experienced transactional attorneys who have practiced at large law and accounting firms, worked as in-house counsel for public companies and investment banks, and owned and operated start-up companies. We understand complex legal matters and provide high quality legal services in a cost-effective manner.  Our clients value our experience, knowledge and judgment.

ENTITY FORMATION

Our team routinely advises clients regarding:

CORPORATE GOVERNANCE

Emerge attorneys also advise on-going concerns with: